Expert Financial Analysis & Reporting on Biotech & Pharmaceutical Companies

Northwest Biotherapeutics: FDA Statement Regarding Use of External Controls in Clinical Trials is a Huge Positive

Posted by Larry Smith on Jan 21, 2022 • (0)

I put out a blog last week alerting subscribers that I am writing an update on Northwest Biotherapeutics. I continue to work on this report and hope to have it out soon, but I am compelled to address some late breaking news beforehand. As the report stood yesterday, I was highlighting as a major uncertainty […]

Recent Reports

Northwest Biotherapeutics: FDA Statement Regarding Use of External Controls in Clinical Trials is a Huge Positive (0)

Recent Blogs

Northwest Biotherapeutics (0)
Northwest Biotherapeutics Issues Encouraging Update on Manufacturing Capabilities (NWBO, $1.59, Buy) (0)
Cryoport: Strength in Stock (0)
Antares: The Future Looks Really, Really Bright (ATRS, Buy, $4.18) (0)
Could There Have Been Hundreds of Millions or Even More Than a Billion Counterfeit Shares of Northwest Biotherapeutics Created Through Illegal Naked Shorting? (0)
Cryoport: Update on My Investment Thinking (CYRX, Buy, $49.35) (0)
Encouraging Comments on DCVax-L from a Key Opinion Leader (0)
Repligen: Some Thoughts for 2021 (RGEN, $223.28) (0)
What Will Happen to SmithOnStocks (0)
Cytokinetics: Catalysts for 2021 (CYTK, $18.79) (0)
Closing Subscriptions to SmithOnStocks and Issuing Refunds (0)

«Older Posts

Expert Financial Analysis and Reporting

Northwest Biotherapeutics: FDA Statement Regarding Use of External Controls in Clinical Trials is a Huge Positive

Recent Reports

Recent Blogs

Recent Posts

Recent Comments

Archives

Categories

Meta